medigraphic.com
ISSN 1817-5996 (Electronic)

2014, Number 1

<< Back Next >>

Rev Cub de Reu 2014; 16 (1)

Calcinosis cutis in the course of Crest´ Syndrome

Acuña AWF, Bautista VMA, Cortes G, Hernández TL, Valdés VJL, Serra VMÁ

Language: Spanish
References: 20
Page: 41-46
PDF size: 431.62 Kb.


ABSTRACT

Systemic sclerosis is an chronic multiorganic entity of unknown cause, with immunologic association. This pathology is classified in diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis, in the second the skin thickness is in fingers, called “sclerodactilia”, distal part of extremities and the face, has been associate to Crest syndrome. Is defined as presence of calcinosis, Raynaud phenomenon, gastroesophageal reflux, sclerodactilia and telangiectasia. 35 years female with Crest syndrome diagnosis, where the principal manifestation is calcinosis cutis associated inflammatory lessons in anterior iliac spine, confused with bacterial abscess. She received surgical treatment with satisfactory evolution. We can conclude this treatment gave us, internal medicine and surgical department knowledgment to Crest syndrome treatment where the principal expression is calcinosis, easily confuse with septic processes where knowledge of personal record and semiology characteristics of calcic secretion hasn’t. One more time we can know the importance of a multidisciplinary work in the rheumatic diseases treatment.


REFERENCES

  1. Varga J, Abraham DJ. Systemic sclerosis: Paradigm multisystem fibrosing disorder. J Clin Invest. 2007;117:557-67.

  2. Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford). 2005;44:1212-6.

  3. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625-31.

  4. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41(7):793-800.

  5. Gabrielli A, Avvedimento EV, Krieg T. Review of epidemiology, pathogenesis, clinical manifestation, diagnosis, histolopathology, differential diagnosis, and treatment. Scleroderma. N Engl J Med. 2009;360:1989-2003.

  6. Rosenbloom J, Castro SV, Jimenez SA. Narrative review. Fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152:159-66.

  7. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. Journal of Rheumatology. 2003;30:755-59.

  8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism. 1980;23:581-90.

  9. Medsger TA. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th edition. Philadelphia: Ed. Lippincott Williams & Wilkins; 2000. p. 1590-624.

  10. Valentini G, Bencivelli W, Bombardieri S, D’Angelo S, Della Rossa A, Silman AJ, Vlachoyiannopoulos PG. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Annals of the Rheumatic Diseases. 2003;62(9):901-03.

  11. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476-81.

  12. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40:78-83.

  13. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins G. A case-controlled study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697-703.

  14. Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L. The scleroderma kidney: progress is risk factors, therapy, and prevention. Curr Rheumatol Rep. 2011;13:37-43.

  15. Chen AY, Zirwas MJ, Heffernan MP. Nephrogenic systemic fibrosis: a review. J Drugs Dermatol. 2010;9:829-34.

  16. Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomarkers in medicine. 2010;4(1):133-47

  17. Tashkin DP, Celli B, Senn S, Goldin J, Roth MD, Furst DE, Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.

  18. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, du Bois RM. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-70.

  19. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006;367:1683-91.

  20. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Keystone EC. Mortality in systemic sclerosis (scleroderma). QJM. 1992;82:139-48.




2020     |     www.medigraphic.com